Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda oncology unit reports positive Velcade trial data

Takeda oncology unit reports positive Velcade trial data

13th December 2010

Takeda's oncology-focused subsidiary Millennium has published new clinical data supporting the safety and efficacy of its multiple myeloma treatment Velcade.

The drug was recently trialled in two studies designed to evaluate the effectiveness of a Velcade induction therapy, followed by single-agent maintenance therapy with the same compound.

In the first of these trials – a phase III study involving 740 previously untreated patients – the drug was shown to improve clinical outcomes among users compared to an alternative regimen.

Meanwhile, the second study – a phase IIIb trial conducted among newly-diagnosed elderly patients – expanded understanding of Velcade's function by comparing three different induction regimes.

Dr Nancy Simonian, chief medical officer at Millennium, said the trials "demonstrated the potential impact of Velcade-based induction and maintenance therapy in prolonging progression-free and overall survival".

This follows the publication of another study earlier this month that illustrated the benefits of a Velcade/rituximab combination among follicular lymphoma patients.ADNFCR-8000103-ID-800286713-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.